Hemocystine is 24 pt has history of cabg and on anti coagulant medication is there any need to do echo
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
homocystinuria echocardiography cardiac surveillance
Finding Sources
Finding Sources
Searching PubMed
homocystinuria cardiovascular management anticoagulation
Reading File
Finding Sources
Searching PubMed
homocystinuria CBS deficiency cardiac complications CABG
Reading File
Reading File
Reading File
Finding Sources
I now have sufficient information to give a thorough, well-sourced answer. Let me compile it.
Homocystinuria - 24-year-old with CABG History on Anticoagulants: Need for Echocardiography?
Quick Clinical Picture
This is a high-risk patient. Classical homocystinuria (cystathionine beta-synthase deficiency) is a systemic metabolic disorder with life-threatening vascular complications that can affect coronary, renal, and cerebral arteries even in the first decade of life. A 24-year-old who has already undergone CABG represents the severe end of this spectrum.
Why Echo is Strongly Indicated - Multiple Reasons
1. Ongoing Vascular Surveillance in Homocystinuria
Homocystinuria causes premature, aggressive vascular disease via endothelial dysfunction, smooth muscle proliferation, and a profoundly prothrombotic state. The coronary arteries are a primary target. Post-CABG surveillance echo helps assess:
- Graft function and wall motion abnormalities - graft occlusion can be silent in young patients
- LV systolic and diastolic function - prior MI(s) may have caused cardiomyopathy
- Pulmonary pressures - venous thromboembolism is common in homocystinuria and can cause pulmonary hypertension
Per Andrews' Diseases of the Skin: "Half of all patients will have a serious vascular event before age 30, and 25% experience a serious event before age 16." This means ongoing monitoring, not a one-time evaluation.
2. Homocystinuria is Directly Cardiotoxic
Per Harrison's Principles of Internal Medicine (22e): "Life-threatening vascular complications (affecting coronary, renal, and cerebral arteries) can occur during the first decade of life and are the major cause of morbidity and mortality." With total plasma homocysteine often >100 µM in uncontrolled disease, the myocardium and valves face ongoing toxic injury.
3. Aortic Root / Valve Assessment
Homocystinuria can mimic Marfanoid features. Per The Wills Eye Manual: echocardiography is specifically recommended "to rule out aortic aneurysms" in this population. Aortic dilatation and mitral valve prolapse are recognized associations. This is especially relevant before any future procedures or anesthesia.
4. Anticoagulant Therapy Monitoring
The patient is on anticoagulation - most likely warfarin or a DOAC for post-CABG thromboprophylaxis AND/OR for the high baseline thrombotic risk of homocystinuria itself. Echo helps:
- Confirm there is no intracardiac thrombus (particularly LV thrombus if LV function is impaired)
- Assess valve function (for deciding INR targets if on warfarin)
- Identify any new regional wall motion abnormalities suggesting re-occlusion
5. Perioperative / Procedural Planning
Any future surgical or invasive procedure in a homocystinuria patient carries extreme thromboembolic risk. Per Wills Eye Manual: "high incidence of thromboembolic events (particularly with general anesthesia)." A current baseline echo is essential for pre-procedural risk stratification.
Summary: Echo Indications at a Glance
| Indication | Rationale |
|---|---|
| Post-CABG graft surveillance | Assess graft patency / LV wall motion |
| LV function assessment | Prior MI may have caused cardiomyopathy |
| Aortic root evaluation | Aneurysm risk in homocystinuria |
| Valve assessment | MVP, aortic regurgitation screening |
| Pulmonary hypertension screen | VTE sequelae common in homocystinuria |
| Anticoagulation management | LV thrombus exclusion; INR target guidance |
| Baseline for future procedures | High anesthetic thrombotic risk |
Metabolic Co-management Reminder
Echo findings should be interpreted alongside metabolic control. Ensure the patient is on:
- Pyridoxine (25-500 mg/day) - effective in ~50% of CBS-deficiency patients
- Betaine - lowers homocysteine via remethylation
- Folate + vitamin B12 supplementation
- Methionine-restricted diet
- Anticoagulation (already on)
Optimal metabolic control reduces the rate of new vascular events significantly and may impact long-term cardiac prognosis.
Bottom line: Yes, echocardiography is clearly indicated in this patient - not just once, but as part of regular scheduled surveillance (typically every 1-2 years, or sooner if symptoms change). The combination of homocystinuria, prior CABG at age 24, and anticoagulant use makes this a mandatory monitoring tool.
- Harrison's Principles of Internal Medicine, 22e, p. 3414
- Andrews' Diseases of the Skin, 5e, p. 469
- Wills Eye Manual, p. 1026
This is a shared conversation. Sign in to Orris to start your own chat.